Panellists voted by 8 to 3 – with one abstention – to change the CDC recommendations to state that MMRV is not recommended ...

In today's pharmaphorum podcast, host Jonah Comstock speaks with Alice Valder Curran, a partner at Hogan Lovells and our ...

Alzheimer’s and Parkinson’s pipelines are rapidly expanding beyond amyloid and into next-generation mechanisms such as ...

There is only one approved drug for ultra-rare disease fibrodysplasia ossificans progressiva (FOP) on the US market, but ...

The $14.50-per-share deal equates to a purchase price of $2.4 billion at closing, with Roche dangling another $6 per share in ...

UK-based electronRx will launch a digital health technology (DHT) to help patients with respiratory disease manage their ...

Novo Nordisk is also ahead in the race to bring an oral GLP-1 to market for weight loss, as it has already filed semaglutide for FDA approval, with a decision before the end of this year, while Lilly ...

The importance of AI in pharma and life sciences cannot be overstated. Regardless of the aspect of industry you examine, ...

As President Donald Trump started his state visit to the UK, GSK unveiled a massive $30 billion investment in manufacturing ...

Onsite in Princeton, New Jersey for the Axtria Ignite 2025 conference, web editor Nicole Raleigh spoke with Ritesh Mehra, CFO ...

Dr Susan Monarez told lawmakers today that Health and Human Services (HHS) Secretary Robert F Kennedy Jr said he planned to ...

AstraZeneca's immunotherapy Imfinzi is the first drug therapy to be recommended for routine NHS use as a treatment for ...